作者

Dr. Manja Epping

合伙人

Read More

Dr. Anja Lunze, LL.M.

合伙人

Read More

Matthew Royle, Ph.D.

合伙人

Read More

Judith Krens

合伙人

Read More
作者

Dr. Manja Epping

合伙人

Read More

Dr. Anja Lunze, LL.M.

合伙人

Read More

Matthew Royle, Ph.D.

合伙人

Read More

Judith Krens

合伙人

Read More

2020年4月29日 |

Everything biologic and biosimilar in-house counsel need to know about COVID-19

In the first session of our 2020 webinar series, we discussed the key responses to the COVID-19 pandemic in Europe and the United States that impact biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, they are facing a great deal of uncertainty due to ever-changing emergency policies aimed at addressing COVID-19.

In this session we focussed on critical developments impacting biologic and biosimilar companies, including:

  • regulatory responses and challenges in the US and Europe
  • changes in patent office policies and proceedings
  • developments in the court systems, and
  • dealing with contractual and supply chain issues.
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

centrifuge-machine
酒店与休闲

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

2020年7月27日
QUICK READ

作者

点击此处了解更多
酒店与休闲

The Bolar and related exemptions in Europe

What activity do they cover?

2020年3月5日

作者

点击此处了解更多

相关活动